Physician profile
Ted Roth
NPI 1174503866
$13,759.28
in general payments reported to CMS, 2019-2025
23 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,353 · 2020: $709 · 2021: $3,543 · 2022: $4,026 · 2023: $1,796 · 2024: $1,446 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,940 · Honoraria: $141 · Consulting Fee: $30.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,939.79 |
| Honoraria | $141.00 |
| Consulting Fee | $30.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $9,196.48 | 2020-2024 | Axonics |
| Boston Scientific Corporation | $771.42 | 2019-2025 | Axonics |
| Caldera Medical, INC | $757.80 | 2019-2024 | Desara |
| Medtronic USA, INC. | $715.62 | 2019-2020 | |
| Astellas Pharma US INC | $395.87 | 2019-2024 | Veozah |
| Hologic Sales and Service, LLC | $293.46 | 2019-2025 | Fluent Fluid Management System, Myosure Tissue Removal Device, Omni Hysteroscope |
| Sumitomo Pharma America, INC. | $235.52 | 2023-2025 | Gemtesa, Myfembree |
| Medtronic, INC. | $215.33 | 2021-2024 | Ligasure |
| Urovant Sciences INC | $161.03 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $159.00 | 2024 | |
| Abbvie INC. | $154.91 | 2019-2022 | |
| Pfizer INC. | $125.71 | 2020-2022 | |
| Smith+Nephew, INC. | $110.14 | 2025 | Pico 7 |
| Mallinckrodt Enterprises LLC | $100.00 | 2019 | |
| Aspira Women'S Health INC | $71.22 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $67.41 | 2019 | |
| Coopersurgical, INC. | $56.70 | 2025 | Sos |
| Laborie Medical Technologies Corp. | $56.67 | 2023 | |
| Myovant Sciences INC. | $42.74 | 2022 | |
| Amag Pharmaceuticals, INC. | $28.92 | 2019 | |
| Therapeuticsmd, INC. | $16.14 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.80 | 2019 | |
| Duchesnay USA Incorporated | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.